VLRX - Valeritas Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3749
+0.0123 (+3.39%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.3626
Open0.4000
Bid0.3600 x 1800
Ask0.4096 x 1200
Day's Range0.3700 - 0.4000
52 Week Range0.3130 - 4.7200
Volume1,371,091
Avg. Volume1,324,625
Market Cap37.471M
Beta (3Y Monthly)15.26
PE Ratio (TTM)N/A
EPS (TTM)-3.5590
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • GlobeNewswire17 days ago

    Valeritas CEO John Timberlake to Participate as a Panelist on “Exploring Innovation in Diabetes Tech,” at DeviceTalks West Conference

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that John Timberlake, CEO, will be a panelist at DeviceTalks West, a MassDevice resource, being held December 11-12, 2018, at the Hilton Orange County/Costa Mesa in Costa Mesa, California. Mr. Timberlake will participate in a panel titled, “Exploring Innovation in Diabetes Tech," scheduled on Wednesday, December 12, 2018, from 11:00-11:45 AM Pacific Time. Mr. Timberlake, along with representatives from other diabetes device companies, will discuss current and future technologies for patients with diabetes.

  • GlobeNewswire19 days ago

    Study Supports Valeritas’ V-Go® Can Improve Glycemic Control in Type 2 Patients When Using an Easy to Follow Physician-Driven Insulin Titration Algorithm

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced the publication of a manuscript titled “Evaluation of a Weekly Physician-Driven Bolus Titration Algorithm in Patients with Type 2 Diabetes Prescribed V-Go® Wearable Insulin Delivery Device for Basal-Bolus Therapy,” in a special Bolus Insulin issue of Annals of Diabetes, Metabolic Disorders & Control, an international, peer-reviewed journal.

  • Thomson Reuters StreetEvents23 days ago

    Edited Transcript of VLRX earnings conference call or presentation 9-Nov-18 1:30pm GMT

    Q3 2018 Valeritas Holdings Inc Earnings Call

  • GlobeNewswire29 days ago

    Valeritas Announces Pricing of $36 Million Public Offering

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced the pricing of its underwritten public offering of (i) 75 million shares of its common stock, (ii) series A warrants to purchase 75 million shares of its common stock and (iii) series B warrants to purchase 75 million shares of its common stock, for gross proceeds of $36 million, at a public offering price of $0.48 per share and accompanying warrants. The series A warrants have an exercise price of $0.60 per share, are immediately exercisable and will expire on the fifth anniversary of the date of issuance.

  • GlobeNewswirelast month

    Investor Expectations to Drive Momentum within Townsquare Media, Koss, ESSA Pharma, MVC Capital, Valeritas, and Sonic Foundry — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswirelast month

    Valeritas Signs Exclusive Middle East Distribution Agreement with Julphar

    Valeritas Holdings, Inc. (VLRX), a medical technology company, has signed an exclusive distribution agreement with Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, for the commercialization of its V-Go Wearable Insulin Delivery device in the GCC (Gulf Cooperation Council). V-Go® Wearable Insulin Delivery device is a simple, all-in-one, wearable insulin delivery option for adult patients with diabetes. Under the terms of the agreement, Julphar will have the rights to promote, market, and sell V-Go to diabetes clinics and patients in the GCC.

  • GlobeNewswirelast month

    Valeritas Reports Record Revenue for the Third Quarter 2018

    - Company’s Third Consecutive Quarter with Greater than 30% Year-Over-Year Revenue Growth - BRIDGEWATER, N.J., Nov. 09, 2018 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a.

  • GlobeNewswirelast month

    Valeritas to Report Third Quarter 2018 Results November 9, 2018

    BRIDGEWATER, N.J., Nov. 05, 2018 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.

  • GlobeNewswire2 months ago

    Valeritas Announces That V-Go® Insulin Delivery Device Has Launched in Italy

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, announced today V-Go has launched and is now available in Italy through its previously disclosed exclusive distribution agreement with Movi SpA (“Movi”). “We are happy to announce the V-Go Wearable Insulin Delivery device is now available in Italy for patients with type 2 diabetes,” said Valeritas CEO, John Timberlake.

  • GlobeNewswire2 months ago

    Valeritas Wins Fifth Consecutive Cardinal Health Supply Chain Excellence Award

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, announced today it has been awarded a Cardinal Health Supply Chain Excellence Award for the fifth consecutive year. “Receiving the Cardinal Health Supply Chain Excellence Award for the fifth consecutive year demonstrates our strong commitment to our V-Go customers,” said John Timberlake, President and Chief Executive Officer of Valeritas. Cardinal Health is a global, integrated healthcare services and products company, providing customized solutions for hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide.

  • ACCESSWIRE2 months ago

    Valeritas Holdings Revenues Grow on Acceptance of V-Go for Insulin, Analyst Report

    NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Valeritas Holdings, Inc. (VLRX), a commercial-stage medical technology company focused on people with diabetes by developing and commercializing innovative technologies. Valeritas' flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots.

  • GlobeNewswire2 months ago

    Valeritas Expects to Report Record Revenue for Third Quarter 2018

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced preliminary financial results for the third quarter of 2018. On a preliminary basis, Valeritas expects to record revenue for the third quarter ended September 30, 2018 of approximately $6.9 million, up approximately 36% over the third quarter of 2017.

  • GlobeNewswire2 months ago

    Valeritas is a Contributing Supporter of the Interactive Insulin Workshop at MEDS East Summit

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced they are supporting interactive insulin workshops at the Metabolic & Endocrine Disease Summit (MEDS) in Orlando, Florida. This four-day summit is the second of two semiannual conferences designed to advance the education of nurse practitioners and physician assistants who treat people with metabolic and endocrine diseases. As with the MEDS Summit that took place in April in San Diego, Valeritas is helping to support the 3.5-hour interactive Insulin Workshop.

  • GlobeNewswire2 months ago

    Persistent Use of Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Significant Clinical & Economic Benefits Compared to Conventional Insulin Delivery in Patients with Type 2 Diabetes

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, announced today the publication this week of a manuscript titled “Clinical and Economic Considerations Based on Persistency with a Novel Insulin Delivery Device versus Conventional Insulin Delivery in Patients with Type 2 Diabetes: A Retrospective Analysis” in Research and Social Administrative Pharmacy, an international, peer-reviewed journal. Insulin delivery options have advanced over the years, but questions remain regarding whether persistent use of these latest innovations offers benefits over the conventional insulin delivery (CID) methods of insulin pen devices or insulin syringes.

  • GlobeNewswire2 months ago

    Valeritas’ V-Go® Demonstrates Benefits Versus Multiple Daily Injections in Patients with Type 2 Diabetes

    BRIDGEWATER, N.J., Oct. 02, 2018 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, a simple,.

  • GlobeNewswire3 months ago

    Valeritas Begins Medical Device Registration Process in China for Its V-Go® Wearable Insulin Delivery Device

    As part of this process, Valeritas has signed an agreement with an international contract research organization (CRO), who has extensive experience in China, who will work directly with the China National Drug Administration (CNDA) to complete the necessary requirements to gain regulatory approval for V-Go in China.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of VLRX earnings conference call or presentation 7-Aug-18 8:30pm GMT

    Q2 2018 Valeritas Holdings Inc Earnings Call

  • ACCESSWIRE4 months ago

    Valeritas Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Valeritas Holdings, Inc. (NASDAQ: VLRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...

  • ACCESSWIRE5 months ago

    Free Pre-Market Technical Recap on DENTSPLY SIRONA and Three Additional Medical Supplies Stocks

    On Monday, July 30, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Seven out of nine sectors ended Monday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS), and Valeritas Holdings Inc. (NASDAQ: VLRX).